Navigation Links
Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
Date:8/25/2013

linical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Amgen develops product candidates internally and through licensing collaborations, partnerships, joint ventures and acquisitions.
Product candidates that are derived from relationships or acquisitions may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with Amgen's products after they are on the market.  Amgen's business may be impacted by government investigations, litigation and product liability claims.  If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, it  could become subject to significant sanctions.  Amgen depends on third parties for a significant portion of its manufacturing capacity for the supply of certain of its current and future products and limits on supply may constrain sales of certain of its current products and product candidate development.

In addition, sales of Amgen's products are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement.  Government and others' regulations and reimbursement policies may affect the development, usage and pricing of Amgen's products.  In addition, Amgen competes with other companies with respect to some of its marketed products as well as for the discovery and development of new products.  Amgen believes that some of its newer product
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... A new analysis and infographic released ... Hepatitis C medications could range from hundreds of millions of ... Hepatitis C receive treatment through state programs. The analysis, which ... on public programs, comes at a time when state and ... Gilead Sciences, Harvoni and Sovaldi. ...
(Date:6/30/2015)...  Inari Medical, Inc. announced today that it has ... The financing was led by members of the board ... Venture Partners.  The round also included participation by several ... pleased to complete this financing with the support of ... who joined in February 2015 as President and Chief ...
(Date:6/30/2015)... 30, 2015 Oramed Pharmaceuticals Inc. ... pharmaceutical Company focused on the development of oral drug ... been screened in the Company,s Phase IIb trial of ... will be performed under the active Investigational New Drug ... Drug Administration (FDA). The Phase IIb study ...
Breaking Medicine Technology:New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State 2New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State 3New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State 4Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 2Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 3
... Mass.--(BUSINESS WIRE)--Jul 9, 2007 - Pro-Pharmaceuticals,Inc. (Amex: ... updated the progress of its Phase II,clinical ... cancer patients who are unable to tolerate ... trial for first-line,treatment of biliary cancer patients. ...
... Late-breaking Phase III,clinical trial data presented today ... Haemostasis (ISTH) Congress demonstrate,that once-daily rivaroxaban achieved ... (VTE) in patients undergoing,knee replacement surgery in ... of care. Patients in the RECORD3,(REgulation of ...
Cached Medicine Technology:Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 2Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 3Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 4Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 5Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5
(Date:6/30/2015)... FL (PRWEB) , ... June 30, 2015 , ... According ... doubled from 2007 to 2013 while heroin-related deaths more than tripled in the same ... threat (1). Novus Medical Detox Center , a leading Florida-based drug treatment facility, ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... According to ... received a $3.1 million grant to study how sensory stimuli can be used to ... emphasis on improving care for children with autism, will compare patient experience in a ...
(Date:6/30/2015)... ... June 30, 2015 , ... Lakeview Health, a drug and ... size of its medical staff to further enhance its ability to treat addiction ... practitioners and physician assistants -- now totals 17, compared to 7 in 2013, ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... pending in a federal multidistrict litigation now underway in the U.S. District Court, ... monthly Status Conference. According to the Court’s calendar, that conference has now been ...
(Date:6/30/2015)... ... 30, 2015 , ... Dr. Sammy Masri of Masri Sports Medicine &Wellness, NJ ... the diagnosis and treatment of non-surgical sports and other musculoskeletal injuries for both adults ... athletics and use exercise to stay healthy and active. Dr. Masri seeks to provide ...
Breaking Medicine News(10 mins):Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 4Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 3Health News:Lakeview Health, a Nationally Recognized Drug Rehabilitation Center in Florida, Doubles Size of Medical Staff 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 2Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 3Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 4Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 5
... Researchers have discovered that some women carry a genetic ... respond to ovarian stimulating hormones during fertility treatment. The ... devising personalised fertility treatments that could bypass the problem ... told the 26th annual meeting of the European Society ...
... ... based laboratory equipment repair and instrument calibration services company, has been formally approved ... lab., , ... (PRWEB) June 29, 2010 -- Beginning in 2009, the AL-TAR Quality Department ...
... Want to lose ... weight off permanently and enjoy top physical fitness levels? See what Brilliance Weight Loss has to ... (PRWEB) June 29, ... and its customer base, as it continues to gain success with showing people how to ...
... Azmacort and ... an equivalent medication. Many have chosen to write into the People,s Medicine Community to express ... Learn more about the FDA,s decision and connect with other individuals through this special report. ... Westlake Village, CA (PRWEB) ...
... By Randy Dotinga HealthDay Reporter , MONDAY, June ... who take the cholesterol-lowering drugs known as statins are a ... But don,t demand that your doctor prescribe a statin ... for you just yet. The findings aren,t firm enough ...
... immune cell known to cause chronic inflammation in autoimmune ... low back pain associated with herniated discs, according to ... finding implicates the cytokine molecule interleukin-17, and supports the ... role in disc disease, says William J. Richardson, MD, ...
Cached Medicine News:Health News:Study finds why some women are sub-fertile with a poor response to ovarian stimulating hormones 2Health News:Study finds why some women are sub-fertile with a poor response to ovarian stimulating hormones 3Health News:AL-TAR Services, Inc. Laboratory Is Now Accredited For ACLASS Standards 2Health News:Brilliance Weight Loss Takes Dieters Beyond Trendy Low Fat Diets 2Health News:Impact of Azmacort Withdrawal Brought to Light in Medicine Community 2Health News:Impact of Azmacort Withdrawal Brought to Light in Medicine Community 3Health News:Impact of Azmacort Withdrawal Brought to Light in Medicine Community 4Health News:Impact of Azmacort Withdrawal Brought to Light in Medicine Community 5Health News:Statins May Lower Rates of Prostate Cancer Recurrence 2Health News:Surprising find may yield new avenue of treatment for painful herniated discs 2
... Stainless steel spiral reinforced. X-ray opaque . Low ... Flange: The flange can be adjusted along the ... cervical soft tissue. The lock ring is turned ... the shaft. Maximum Patient Comfort: The tube is ...
... Per-fit™ tubes are a dual ... of the disposable inner cannula ... provided in the procedural tray. ... tubes are available separately. Per-fit™ ...
Manufactured form the same soft siliconized PVC as all Portex® Blue Line® tracheostomy tubes....
Thermosensitivity of material allows tube to conform to patients anatomy for maximum patient comfort....
Medicine Products: